Posted On: 08/20/2013 5:06:07 PM
Post# of 36729
On June 30, 2013, SK3 Group closed an acquisition agreement to acquire 100% of the outstanding shares of BBORL, INC (Berkeley Bio-Organic Research Laboratories), a California Corporation from its four shareholders for 20 million shares of SK3 Group, common stock (5
million shares to each shareholder). The main concentration of BBORL is consultation with many collectives in the development and production of non-psychoactive cannabinoid medicines, primarily for the treatment of cancer, allowing patients to obtain medically efficacious doses without attendant, and possibly negative, psychoactive consequences. A secondary interest is the development and production of equipment for the manufacture and production of cannabinoid-based medicines. Berkeley Bio has made substantial strides in these areas.
million shares to each shareholder). The main concentration of BBORL is consultation with many collectives in the development and production of non-psychoactive cannabinoid medicines, primarily for the treatment of cancer, allowing patients to obtain medically efficacious doses without attendant, and possibly negative, psychoactive consequences. A secondary interest is the development and production of equipment for the manufacture and production of cannabinoid-based medicines. Berkeley Bio has made substantial strides in these areas.
(0)
(0)
